MERVYN TURNER, PhD
Dr. Mervyn Turner has nearly 35 years of experience in pharmaceutical drug discovery, research and development, licensing and business development, emerging markets strategy development and implementation. He currently operates his own consulting firm, MJ Turner Consulting, where he counsels biotech, pharma, venture capital and investment banking firms. Dr. Turner spent 27 years at Merck & Co. Inc in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For seven years, he was head of world-wide licensing and external research at Merck before becoming Merck’s first Chief Strategy Officer and a member of the senior executive team in 2008. He retired from the company in 2011 and is currently an Advisor to Bay City Capital, a San Francisco-based venture firm, and Bridge Medicines, a commercial incubator for early stage innovation based in New York City, He also is a Senior Advisor to the Healthcare group of Lazard, a leading financial services and investment banking firm. Dr. Turner holds his PhD in Chemistry from the University of Sheffield.